The following is an article released by Rheumatology Advisor:
Switching between biologic agents is common among patients with juvenile idiopathic arthritis (JIA), with inadequate response being the most reason for the switch, according to study results published in Journal of Clinical Rheumatology.
Participants were aged 18 years and younger and were diagnosed with JIA before the age of 16 years. The diagnosis was consistent with the International League of Rheumatology Societies criteria. In addition, eligible participants received treatment with more than 1 biologic agent between January 2009 and 2022.
The study authors concluded that clinicians and researchers should be alert to the need for patients undergoing JIA treatment to change protocols. They noted, “[A total of 25%] of patients undergoing biological drug treatment may require biological agent switching.”
You can read the full article here.